Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  European Heart Journal

• Publication date

  2002-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/EUHJ.2001.3151PMID 12090748
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• UvA-DARE ( Digital Academic Repository ) Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina : the CAPTURE study

  2017cited by this paper
• Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease

  2001cited by this paper
• Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT.

  2000cited by this paper
• Commentary on and reprint of EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) Investigators, The, Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, in New England Journal of Medicine (1994) 330:956–961

  2000cited by this paper
• Canadian-American Differences in the Management of Acute Coronary Syndromes in the GUSTO IIb Trial: One-Year Follow-Up of Patients Without ST-Segment Elevation

  2000cited by this paper
• The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.

  2000cited by this paper
• Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators.

  2000cited by this paper
• Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.

  2000cited by this paper
• Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators.

  2000cited by this paper
• Management of Patients With Acute Coronary Syndromes in the United States by Platelet Glycoprotein IIb/IIIa Inhibition: Insights From the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial

  2000cited by this paper
• Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management.

  1999cited by this paper
• Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban

  1999cited by this paper
• Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators.

  1999cited by this paper
• Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators.

  1999cited by this paper
• Glycoprotein IIb/IIIa integrin blockade.

  1998cited by this paper
• Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.

  1998cited by this paper
• Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.

  1998cited by this paper
• Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence.

  1998cited by this paper
• Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators.

  1998cited by this paper
• Acute Coronary Syndromes in the GUSTO-IIb Trial Prognostic Insights and Impact of Recurrent Ischemia

  1998cited by this paper
• Correction: Outcomes in Patients with Acute Non-Q-Wave Myocardial Infarction Randomly Assigned to an Invasive as Compared with a Conservative Management Strategy.

  1998cited by this paper
• Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.

  1997cited by this paper
• Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.

  1997cited by this paper
• Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Compl

  1997cited by this paper
• Risk stratification in unstable angina. Prospective validation of the Braunwald classification.

  1995cited by this paper
• Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

  1994cited by this paper

• Antiplatelet agents for chronic kidney disease.

  2013cites this paper
• Short-term outcome of single-bolus dose of eptifibatide during percutaneous coronary intervention (PCI) in a tertiary level hospital in Bangladesh

  2011cites this paper
• Short-term outcome of single-bolus dose of eptifibatide during percutaneous coronary intervention (PCI) in a tertiary level hospital in Bangladesh

  2011cites this paper
• Intravenous Glycoprotein IIb/IIIa Antagonists

  2009cites this paper
• Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb‐IIIa antagonists

  2004cites this paper